OTCMKTS:RHHBYRoche Holdings AG Basel Stock Price, Forecast & News

$43.09

-1.04 (-2.36 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$42.55

Now: $43.09▼

$44.00

50-Day Range

$39.39

MA: $43.42▼

$45.61

52-Week Range

$32.67

Now: $43.09▼

$46.00

Volume3.39 million shs

Average Volume2.52 million shs

Market Capitalization$295.10 billion

P/E Ratio16.96

Dividend Yield1.67%

Beta0.41

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases. The company's diagnostic solutions include blood gas analysis; blood screening; cancer screening/monitoring; cardiac markers; cardiovascular testing; cholesterol and coagulation monitoring; coagulation routine and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis, heterogeneous immunochemistry, homogeneous immuno assay, immunology, and infectious disease solutions; intensive care testing; monitoring anti platelet therapy; neonatal intensive care units; nucleic acid purification; PCR clinical diagnostics; physical fitness testing; platelet function testing; quality control services; real-time PCR diagnostic systems; urinalysis; and serum work area and workflow solutions. In addition, it offers gene expression, gene sequencing, and real time PCR systems for researchers. The company licenses its products or technologies to third parties. Roche Holding AG has a collaboration agreement with San Francisco-based Syapse to develop software that integrates fragmented clinical, molecular, and data on treatment plans and health outcomes. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Roche Holdings AG Basel has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.00, Roche Holdings AG Basel has a potential upside of 11.4% from its current price of $43.09.
Amount of Analyst Coverage
Roche Holdings AG Basel has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.4 Community Rank

Outperform Votes
Roche Holdings AG Basel has received 300 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Roche Holdings AG Basel has received 322 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Roche Holdings AG Basel has received 51.77% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Roche Holdings AG Basel and other stocks. Vote “Outperform” if you believe RHHBY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RHHBY will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Roche Holdings AG Basel is a leading dividend payer. It pays a dividend yield of 1.67%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Roche Holdings AG Basel does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Roche Holdings AG Basel is 28.35 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Roche Holdings AG Basel will have a dividend payout ratio of 25.99 % next year. This indicates that Roche Holdings AG Basel will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Roche Holdings AG Basel insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.30% of the stock of Roche Holdings AG Basel is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Roche Holdings AG Basel are expected to grow by 6.54% in the coming year, from $2.60 to $2.77 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Roche Holdings AG Basel is 16.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Roche Holdings AG Basel is 16.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.22.
Price to Earnings Growth Ratio
Roche Holdings AG Basel has a PEG Ratio of 3.10. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Roche Holdings AG Basel has a P/B Ratio of 8.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.09 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:RHHBY

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.roche.com

Phone41-61-688-1111

Debt

Debt-to-Equity Ratio0.35

Current Ratio1.30

Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio16.96

Forward P/E Ratio16.57

P/E Growth3.1

Sales & Book Value

Annual Sales$61.87 billion

Price / Sales4.77

Cash Flow$3.12 per share

Price / Cash Flow13.81

Book Value$5.27 per share

Price / Book8.18

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees97,735

Outstanding Shares6,848,488,000

Market Cap$295.10 billion

Next Earnings DateN/A

OptionableNot Optionable

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Roche Holdings AG Basel (OTCMKTS:RHHBY) Frequently Asked Questions

How has Roche Holdings AG Basel's stock been impacted by COVID-19 (Coronavirus)?

Roche Holdings AG Basel's stock was trading at $40.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RHHBY stock has increased by 5.3% and is now trading at $43.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Roche Holdings AG Basel?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche Holdings AG Basel in the last year. There are currently 2 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Roche Holdings AG Basel.

What price target have analysts set for RHHBY?

12 brokerages have issued 1 year price targets for Roche Holdings AG Basel's shares. Their forecasts range from $48.00 to $48.00. On average, they expect Roche Holdings AG Basel's share price to reach $48.00 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price. View analysts' price targets for Roche Holdings AG Basel.

Has Roche Holdings AG Basel been receiving favorable news coverage?

Press coverage about RHHBY stock has been trending extremely positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Roche Holdings AG Basel earned a media sentiment score of 4.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View the latest news aboutRoche Holdings AG Basel.

Who are some of Roche Holdings AG Basel's key competitors?

Some companies that are related to Roche Holdings AG Basel include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Vertex Pharmaceuticals (VRTX). View all competitors.

Who are Roche Holdings AG Basel's key executives?

Roche Holdings AG Basel's management team includes the following people:

Dr. Severin Schwan, CEO & Exec. Director (Age 52)
Dr. Alan Hippe, Chief Financial & Information Officer (Age 52)
Dr. Gottlieb A. Keller, Gen. Counsel & Corp. Sec. (Age 65)
Ms. Cristina A. Wilbur, Head of Group HR (Age 52)
Dr. Karl Mahler, Head of Investor Relations

What is Roche Holdings AG Basel's stock symbol?

Roche Holdings AG Basel trades on the OTCMKTS under the ticker symbol "RHHBY."

Who are Roche Holdings AG Basel's major shareholders?

Roche Holdings AG Basel's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Parametric Portfolio Associates LLC (0.08%), Schafer Cullen Capital Management Inc (0.02%), Douglass Winthrop Advisors LLC (0.01%), Riverbridge Partners LLC (0.01%), Ferguson Wellman Capital Management Inc. (0.01%) and Grimes & Company Inc. (0.00%).

Which major investors are selling Roche Holdings AG Basel stock?

RHHBY stock was sold by a variety of institutional investors in the last quarter, including Schafer Cullen Capital Management Inc, Kempner Capital Management Inc., Parametric Portfolio Associates LLC, Oxbow Advisors LLC, Scout Investments Inc., Fisher Asset Management LLC, Kornitzer Capital Management Inc. KS, and Taylor Cottrill Erickson & Associates Inc..

Which major investors are buying Roche Holdings AG Basel stock?

RHHBY stock was purchased by a variety of institutional investors in the last quarter, including Park National Corp OH, S&T Bank PA, Jolley Asset Management LLC, Douglass Winthrop Advisors LLC, Chartwell Investment Partners LLC, Hancock Whitney Corp, Anderson Hoagland & Co., and Ferguson Wellman Capital Management Inc..

How do I buy shares of Roche Holdings AG Basel?

Shares of RHHBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Roche Holdings AG Basel's stock price today?

One share of RHHBY stock can currently be purchased for approximately $43.09.

How big of a company is Roche Holdings AG Basel?

Roche Holdings AG Basel has a market capitalization of $295.10 billion and generates $61.87 billion in revenue each year. The company earns $13.58 billion in net income (profit) each year or $2.54 on an earnings per share basis. Roche Holdings AG Basel employs 97,735 workers across the globe.

What is Roche Holdings AG Basel's official website?

The official website for Roche Holdings AG Basel is www.roche.com.

How can I contact Roche Holdings AG Basel?

Roche Holdings AG Basel's mailing address is GRENZACHERSTRASSE 124, BASEL V8, CH-4070. The company can be reached via phone at 41-61-688-1111 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff